BUCLIZINE

First approved in 1954

Details

Stereochemistry	RACEMIC
Molecular Formula	C28H33ClN2
Molecular Weight	433.028
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(C)C1=CC=C(CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(Cl)C=C4)C=C1

InChI

InChIKey=MOYGZHXDRJNJEP-UHFFFAOYSA-N

InChI=1S/C28H33ClN2/c1-28(2,3)25-13-9-22(10-14-25)21-30-17-19-31(20-18-30)27(23-7-5-4-6-8-23)24-11-15-26(29)16-12-24/h4-16,27H,17-21H2,1-3H3

HIDE SMILES / InChI

Molecular Formula	C28H33ClN2
Molecular Weight	433.028
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.drugs.com/mmx/buclizine-hydrochloride.html
Curator's Comment: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/22469258 | http://edudrugs.com/B/Bucladin-S.html

Buclizine, a piperazine derivative, is a sedating antihistamine with antimuscarinic and moderate sedative action. The drug is used mainly for its antiemetic action, particularly in the prevention of motion sickness, and in the treatment of migraine in combination with analgesics. The following side/adverse effects have been selected on the basis of their potential clinical significance: drowsiness; Incidence less frequent; blurred vision; dryness of mouth, nose, and throat; headache; nervousness, restlessness, or trouble in sleeping; upset stomach. The following drug interactions have been selected on the basis of their potential clinical significance: alcohol; anticholinergics or other medications with anticholinergic activity; apomorphine.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315 Target ID: CHEMBL231 Sources: https://www.drugs.com/international/buclizine.html \| https://www.ncbi.nlm.nih.gov/pubmed/22469258	Antagonist 2778

Conditions

Condition	Modality	Highest Phase	Product
Motion sickness 43 Sources: https://www.drugs.com/mmx/buclizine-hydrochloride.html	Preventing	Approved 8429	BUCLADIN-S Approved Use For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
Vertigo 17 Sources: http://edudrugs.com/B/Bucladin-S/more.html	Preventing	Approved 8429	BUCLADIN-S Approved Use For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).
Migraine attacks 6 Sources: http://www.hpra.ie/img/uploaded/swedocuments/2138098.PA0823_036_003.653d1899-f57c-4e70-8854-64e357015376.000001leaflet.131121.pdf	Palliative	Approved 8429	Migraleve pink Approved Use Treating nausea and headache associated with migraine attacks that are not relieved by paracetamol, ibuprofen or aspirin alone. Launch Date 1.43251197E12

C_max

Value	Dose	Co-administered	Analyte	Population
0.45 μg/mL EXPERIMENT https://pubs.rsc.org/en/content/articlehtml/2014/ay/c3ay41698d	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		BUCLIZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
5.22 μg × h/mL EXPERIMENT https://pubs.rsc.org/en/content/articlehtml/2014/ay/c3ay41698d	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		BUCLIZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
5.3 h EXPERIMENT https://pubs.rsc.org/en/content/articlehtml/2014/ay/c3ay41698d	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		BUCLIZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY114327
1PlusChem LLC	1P007NQY
AAA Chemistry	AR-1I0822
ABI Chem	AC1L1N6A
ABI Chem	AC1Q3ND3
ACT Chemical	ACT03588
AK Scientific	Q710
AN PharmaTech	AN-43645
Achemo BB	AC-83657
Alsachim	3415	http://www.alsachim.com/product-C4705-glo.bal-view.html
Ambeed	A137542
ApexBio Technology	B1546
AstaTech	F15132
BLD Pharm	BD118924	http://www.bldpharm.com/products/82-95-1.html
BOC Sciences	129-74-8
BOC Sciences	82-95-1
Bide Pharmatech	BD118925
BlocksMatrix Scientific	95477
Bosche Scientific	B3547
Chem Scene	CS-0019690
ChemMol	30105017	http://www.chemmol.com/chemmol/30105017.html
ChemMol	49426643	http://www.chemmol.com/chemmol/49426643.html
ChemMol	99160493	http://www.chemmol.com/chemmol/99160493.html
ChemShuttle	151886
Chemieliva Pharmaceutical Co., Ltd	PBCM1426773
Combi-Blocks	QP-9751
Combi-Blocks	QV-5821
Compound Cloud	65463
Compound Cloud	6729
Hairui	HR120102
Hangzhou APIChem Technology	AC-15954
Hangzhou Yuhao Chemical Technology	YH88401
KeyOrganics	KS-1250
Lab Network	LN03257489	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN03257489
MedChem Express	HY-A0128A
MolPort	MolPort-003-845-425	https://www.molport.com/shop/molecule-link/MolPort-003-845-425
Molcore	MC114327
Molnova	M17929
MuseChem	A000516
MuseChem	I014280
NCI Plated 2007	25141
Nanjing Pope Bio-tech	NSTH-D22335
Norris Pharm	NSTH-D22335
NovoSeek	6729
PI Chemicals	PI-37049
Sigma Aldrich	SML1587\|SIGMA
Sigma Aldrich	SML1591
Sigma Aldrich	SML1591\|SIGMA
Smolecule	S007866	http://www.smolecule.com/products/s007866
Smolecule	S522235	http://www.smolecule.com/products/s522235
Smolecule	S660983	https://www.smolecule.com/products/s660983
THE BioTek	bt-254422	https://www.thebiotek.com/product/inhibitors/bt-254422
THE BioTek	bt-261898	https://www.thebiotek.com/product/inhibitors/bt-261898
TargetMol	T6426
Toronto Research Chemicals	B689450
Toronto Research Chemicals	H939875
Vesino Industrial Co Ltd	VA10436
Wonderchem	WD051YX
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.	PH-1228A
Yuhao Chemical	YH88401	http://www.chemyuhao.com/82-95-1.html
ZINC	ZINC000019364226	http://zinc15.docking.org/substances/ZINC000019364226
ZINC	ZINC000019364228	http://zinc15.docking.org/substances/ZINC000019364228
abcr GmbH	AB464191	http://www.abcr.com/shop/en/AB464191
eMolecules	107022688
eMolecules	300679713
eNovation Chemicals	D553996
mcule	MCULE-5078973080
mcule	MCULE-7696813187

PubMed

Title	Date	PubMed
Development of a list of potentially inappropriate drugs for the korean elderly using the delphi method.	2010 Dec	21818443

Patents

Sample Use Guides

In Vivo Use Guide

50 mg thirty minutes before travel. Dose may be repeated every four to six hours as needed. Usual adult prescribing limits - up to 150 mg daily.

Route of Administration: Oral

In Vitro Use Guide

Treatment of MCF-7 cells with different concentrations for 72 h showed that buclizine (IC50: 19.18 ± 5.32 μM) revealed considerable growth inhibition.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:32:42 UTC 2023` Edited by `admin` on `Fri Dec 15 16:32:42 UTC 2023`
Record UNII	0C94V6X681
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BUCLIZINE

Official Name

English

buclizine [INN]

Common Name

English

BUCLIZINE [MI]

Common Name

English

1-(P-TERT-BUTYLBENZYL)-4-(P-CHLORO-.ALPHA.-PHENYLBENZYL)PIPERAZINE

Common Name

English

BUCLIZINE [VANDF]

Common Name

English

Buclizine [WHO-DD]

Common Name

English

Classification Tree Code System Code

WHO-ATC

R06AE01